Eli Lilly has reported findings from two late-stage clinical trials, LUCENT-2 and VIVID-1, suggesting that its interleukin-23 (IL-23) inhibitor mirikizumab, marketed as Omvoh, offers benefits across multiple aspects of disease control in both ulcerative colitis (UC) and Crohn’s disease (CD). The results point to a treatment approach that extends beyond standard remission measures to address symptoms that matter most to patients day to day.
Ulcerative colitis and Crohn’s disease are the two principal forms of inflammatory bowel disease (IBD), chronic conditions marked by relapsing gut inflammation that can cause pain, diarrhoea, bleeding and fatigue. Mirikizumab works by blocking interleukin-23, a signalling protein that drives much of the inflammatory activity seen in both conditions. It was already established as a licensed option for moderate to severe UC, and the IBD treatment landscape has increasingly focused on biologic and targeted therapies that interrupt specific immune pathways rather than suppressing the immune system broadly. The latest trial data extend the evidence base to include Crohn’s disease alongside further follow-up in ulcerative colitis.
According to the trial summaries cited by Indian Pharma Post, the LUCENT-2 maintenance study in ulcerative colitis and the VIVID-1 study in Crohn’s disease assessed mirikizumab across several dimensions of disease activity, rather than relying solely on standard clinical remission criteria. These included endoscopic improvement, which reflects visible healing of the gut lining, as well as patient-reported measures such as bowel urgency and overall quality of life. The company’s reported analysis framed these as complementary markers that together give a more complete picture of how well a treatment is working, beyond whether symptoms have simply settled. The data were described as showing consistent improvement across these measures in patients treated with mirikizumab compared with those on placebo, reinforcing the rationale for evaluating IBD therapies using a wider set of outcomes rather than a single remission threshold.
For clinicians managing IBD, outcomes such as bowel urgency and quality of life are increasingly recognised as clinically meaningful, even when they do not always track directly with endoscopic or biochemical markers of inflammation. A therapy shown to improve multiple domains simultaneously, rather than one measure at the expense of another, may be particularly relevant for patients whose day-to-day burden stems as much from symptom unpredictability as from inflammation itself. These findings add to the evidence supporting IL-23 inhibition as a treatment class in both ulcerative colitis and Crohn’s disease, though decisions about individual patient care should continue to rest on full appraisal of trial data and established clinical guidance.
Reference
D’Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2023;388(26):2444-2455. doi:10.1056/NEJMoa2207940.
A full peer-reviewed publication for the VIVID-1 Crohn’s disease trial could not be verified from the material supplied for this article. Data relating to VIVID-1 are attributed to Eli Lilly and Company’s reported trial communications, as summarised by Indian Pharma Post.
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.